Brensocatib

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-Cystic Fibrosis Bronchiectasis

Conditions

Non-Cystic Fibrosis Bronchiectasis

Trial Timeline

— → —

NCT ID

NCT05344508

About Brensocatib

Brensocatib is a pre-clinical stage product being developed by Insmed for Non-Cystic Fibrosis Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT05344508. Target conditions include Non-Cystic Fibrosis Bronchiectasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05344508	Pre-clinical	Completed	—	—	Non-Cystic Fibrosis Bronchiectasis
NCT06178783	Phase 1	Completed	Dec 27, 2023	Jan 4, 2024	Healthy Volunteers
NCT05517525	Phase 1	Completed	Oct 4, 2022	Jun 1, 2023	Hepatic Impairment
NCT05673603	Phase 1	Completed	Jul 20, 2021	Feb 14, 2023	Renal Impairment

Competing Products

8 competing products in Non-Cystic Fibrosis Bronchiectasis

See all competitors

Product	Company	Stage	Hype Score
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	77
TIP + TIP and placebo + Placebo	Novartis	Phase 2	52
CSL787 + Placebo	CSL	Phase 2	51
HSK31858, tablet + Placebo	Haisco Pharmaceutical Group	Phase 3	74
HSK31858 + placebo	Haisco Pharmaceutical Group	Phase 2	49
Brensocatib 10 mg + Brensocatib 25 mg + Placebo	Insmed	Phase 2	49
Brensocatib 10 mg + Brensocatib 25 mg + Placebo	Insmed	Phase 3	74
AP-PA02	Armata Pharmaceuticals	Phase 2	44

Other Products from Insmed

Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.Phase 3

Treprostinil Palmitil Inhalation Powder + PlaceboPhase 3

ALIS + Azithromycin + Ethambutol + ELCPhase 3

LAI 590 mg + Multi-drug regimenPhase 3